Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF582 versus Lucentis in neovascular age-related macular degeneration
ACTRN12613001303730Phase 2Completed
- Sponsor
- Pfenex Inc.
- Start
- Jan 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of ranibizumab biosimilar PF582 and ranibizumab in exudative macular degeneration (2 arms), sponsored by Pfenex Inc. Primary endpoint: Safety and tolerability of PF582 versus Lucentis. Started Jan 2014; status: completed.
02
Drugs
ranibizumab biosimilar PF582ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12613001303730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001303730.